Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024. In the quarter to June 2026, revenue grew 69.8%, EPS fell 30.0% and free cash flow fell 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

16.47 0.93 −5.34%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−8.7×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.90 14.69 21.68 15.08
Net Debt/EBITDA
4.53 9.07 9.95 6.72
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.47) (0.59) (0.54) (0.56)
Book value per Share
3.00 7.26 5.20 4.64
Free Cash Flow
(41.63) (51.95) (61.64) (63.87)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates